Edesa Biotech Receives FDA IND Clearance for EB06 Vitiligo Study

Edesa Biotech announced that the FDA cleared its Investigational New Drug application for a Phase 2 clinical study of EB06 in vitiligo. According to GlobeNewswire, the clearance enables expansion of the company’s ongoing study to U.S. investigational sites.

Quiverquant also reported that the FDA cleared the IND application, allowing Edesa to expand patient recruitment to sites in the United States. The regulatory action concerns EB06, Edesa’s investigational treatment program for vitiligo.

FDA clearance supports U.S. study expansion

GlobeNewswire reported that Edesa’s announcement concerns an ongoing Phase 2 vitiligo clinical study. The publisher said the IND clearance enables the company to add U.S. investigational sites to the study.

For pharmaceutical and biotech sales professionals, the reported event is a regulatory clearance tied to the geographic expansion of an active clinical program. The supplied reports describe the clearance as enabling U.S. participation in the study rather than as a marketing authorization for EB06.

Quiverquant similarly characterized the development as an expansion of recruitment to U.S. sites. Both publishers reported the FDA IND clearance on Oct. 15, 2026.

Phase 2 program details reported

According to Quiverquant, the Phase 2 study is intended to evaluate the efficacy of EB06 in adults with moderate-to-severe vitiligo. The publisher described EB06 as a monoclonal antibody targeting CXCL10.

Quiverquant reported that the study may enroll up to 80 adults. GlobeNewswire identified the program as a Phase 2 vitiligo study and said the FDA action enables the expansion to U.S. investigational sites.

Topline data timing

GlobeNewswire reported that Edesa anticipates topline data in Q4 2027. Quiverquant reported the same anticipated timing.

The FDA IND clearance is the central regulatory milestone in Edesa’s reported update. Based on the supplied publisher reports, it enables the stated expansion of the ongoing Phase 2 EB06 vitiligo study to U.S. investigational sites.